Literature DB >> 17934259

Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid.

I Escribano1, J C Rodríguez, B Llorca, E García-Pachon, M Ruiz, G Royo.   

Abstract

OBJECTIVE: Our aim was to study the influence of efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid.
METHODS: We studied the mutations in gyrA and gyrB genes and the influence of efflux pump systems with 2 inhibitors (reserpine and MC 207.110).
RESULTS: The effect of the active efflux system on the decrease in sensitivity to ciprofloxacin, moxifloxacin, levofloxacin, ofloxacin, gatifloxacin and linezolid was studied by investigating the variation in the in vitro activity of these compounds when assayed in association with reserpine and MC 207.110. These inhibitors exhibit activity both in strains that are resistant and in strains that are susceptible to these antibiotics. However, they are seen to be most active in resistant strains, since the minimum inhibitory concentration of the antibiotics studied in these strains was reduced between 2- and 6-fold.
CONCLUSIONS: Therefore, these mechanisms are involved in the resistance to both compounds. It would be of interest to carry out further studies to determine to what extent these active efflux systems influence resistance to the different groups of drugs used in the treatment of tuberculosis, with a view to the possibility of using the inhibitors of these systems in future therapeutic applications. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934259     DOI: 10.1159/000109769

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  33 in total

1.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

Review 2.  A balancing act: efflux/influx in mycobacterial drug resistance.

Authors:  G E Louw; R M Warren; N C Gey van Pittius; C R E McEvoy; P D Van Helden; T C Victor
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

3.  In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.

Authors:  Tsi-Shu Huang; Yung-Ching Liu; Cheng-Len Sy; Yao-Shen Chen; Hui-Zin Tu; Bao-Chen Chen
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

Review 4.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 5.  Do Shoot the Messenger: PASTA Kinases as Virulence Determinants and Antibiotic Targets.

Authors:  Daniel A Pensinger; Adam J Schaenzer; John-Demian Sauer
Journal:  Trends Microbiol       Date:  2017-07-19       Impact factor: 17.079

6.  Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.

Authors:  Paolo Denti; Anneke C Hesseling; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Tjokosela Tikiso; Lubbe Wiesner; Mine de Kock; Jana Winckler; Jennifer Norman; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

7.  Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model.

Authors:  Elise D Pieterman; Lindsey H M Te Brake; Gerjo J de Knegt; Aart van der Meijden; Jan-Willem C Alffenaar; Hannelore I Bax; Rob E Aarnoutse; Jurriaan E M de Steenwinkel
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

8.  Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations.

Authors:  John D Szumowski; Kristin N Adams; Paul H Edelstein; Lalita Ramakrishnan
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 9.  Novel adjunctive therapies for the treatment of tuberculosis.

Authors:  A A Ordonez; M Maiga; S Gupta; E A Weinstein; W R Bishai; S K Jain
Journal:  Curr Mol Med       Date:  2014-03       Impact factor: 2.222

10.  Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.

Authors:  Pooja Singh; Amita Jain; Pratima Dixit; Shantanu Prakash; Indu Jaiswal; Vimala Venkatesh; Mastan Singh
Journal:  J Antibiot (Tokyo)       Date:  2014-07-23       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.